Bioactive Compounds
-
BA1886 Nucleoside-Analog-1Summary: Nucleoside-Analog-1, an analog of antiviral nucleoside R1479, was used in the synthesis of HCV antiviral nucleoside analogs. -
A8965 VTP50469 - BA1885 TrachelogeninSummary: Trachelogenin ((-)-Trachelogenin) is an entry inhibitor with no genotype specificity and low cytotoxicity.
-
A8954 Ac-YVAD-CHO1 CitationTarget: CaspasesSummary: Selective inhibitor of interleukin-1β converting enzyme (ICE; Caspase-1) - BA1884 LJ001Summary: LJ001 is a broad-spectrum antiviral active molecule with oral activity.
-
A8463 Lithocholic AcidTarget: Farnesoid X receptors (FXRs)|Vitamin D receptors (VDRs)|Pregnane X receptor(PXR)Summary: Toxic secondary bile acid; induces intrahepatic cholestasis; FXR antagonist and PXR/SXR agonist - BA1883 SetrobuvirSummary: Setrobuvir (ANA598) is an orally active non-nucleoside polymerase inhibitor.
-
A8399 Ciprofloxacin1 CitationSummary: Topoisomerase inhibitor - BA1882 NCI-B16Summary: NCI-B16 is a small molecule RNA binding agent.
-
A8253 PD 1730745 CitationTarget: VEGFR|FGFRSummary: A highly selective tyrosine kinase inhibitor; an FGFR and VEGFR2 inhibitor.